CRISPLD2

Across TCGA pan-cancer cohorts, CRISPLD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRISPLD2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRISPLD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRISPLD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where CRISPLD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.208	0.960	.002	57	view →
LUAD	OS	Quartile	III,IV	0.280	0.879	.001	20	view →
GBM	DFS	Tertile	All	0.708	0.896	.026	3	view →
PDAC	DFS	Median	III,IV	0.799	0.521	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRISPLD2–CCRCC (DFS)

Open the CCRCC breakdown →